GleamWall
中文EN

AWHL Aspira Women's Health Inc.

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 926617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY112.2%
TTM net income YoY55.8%
TTM EPS YoY71.4%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin1,481.2%
Operating margin-2,079.9%
Net margin-1,520.4%
FCF margin—
EBITDA margin-2,026.1%

Returns

ROE—
ROA-87.8%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets291.9%
Debt / equity—
Current ratio0.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$343,000$4,000
Cost of revenue$3.30M$3.70M
Gross profit$5.92M$5.48M
R&D expense$2.88M$3.27M
SG&A expense$7.96M$10.35M
Operating income-$7.91M-$16.28M
Pretax income-$12.78M-$13.09M
Net income-$12.78M-$13.09M
EBITDA-$7.80M-$16.19M
EPS (basic)-0.37-0.93
EPS (diluted)-0.37-0.93
Weighted avg. shares (diluted)34.10M14.13M
Banking
Net interest income-$41,000-$33,000
Balance sheet
Cash & equivalents$1.75M$1.77M
Receivables$1.21M$990,000
Inventory$256,000$326,000
Current assets$4.06M$4.18M
PP&E, net$47,000$69,000
Intangibles$310,000—
Total assets$5.46M$5.49M
Current liabilities$3.46M$5.47M
Short-term debt$236,000$229,000
Long-term debt$1.04M$1.28M
Total debt$1.28M$1.51M
Total liabilities$12.39M$8.05M
Shareholders' equity-$6.93M-$2.56M
Net debt-$478,000-$262,000
Shares outstanding43.48M17.41M
Cash flow statement
Operating cash flow-$7.03M-$12.11M
Capital expenditure$16,000$37,000
Free cash flow-$7.04M-$12.15M
Investing cash flow-$401,000-$37,000
Financing cash flow$7.42M$11.06M
Depreciation & amortization$112,000$92,000
Stock-based compensation$531,000$1.49M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.